Online Program Home
  My Program

Abstract Details

Activity Number:
Register
214037 - Bayesian and Frequentist Adaptive Methods for Clinical Trials (ADDED FEE)
Type: Professional Development
Date/Time: Sunday, July 30, 2017 : 8:30 AM to 5:00 PM
Sponsor: ASA
Abstract #325468
Title: Bayesian and Frequentist Adaptive Methods for Clinical Trials (ADDED FEE)
Author(s): Peter Mueller* and Frank Bretz* and Byron Jones*
Companies: UT Austin and Novartis AG and Novartis Pharma
Keywords:
Abstract:

Clinical trials play a critical role in pharmaceutical drug development. New trial designs often depend on historical data, which, however, may not be accurate for the current study due to changes in study populations, patient heterogeneity, or different medical facilities. As a result, the original plan and study design may need to be adjusted or even altered to accommodate new findings and unexpected interim results. Through carefully thought-out and planned adaptation, the right dose can be identified faster, patients can be treated more effectively, and treatment effects evaluated more efficiently.

This one-day short course will introduce various adaptive methods for Phase I to Phase III clinical trials using both, frequentist and Bayesian methods. Accordingly, different types of adaptive designs will be introduced and illustrated with case studies. This includes dose escalation/de-escalation and dose insertion based on observed data, adaptive dose finding studies using optimal designs to allocate new cohorts of patients based on the accumulated evidence, population enrichment designs, early stopping for toxicity, futility, or efficacy using group-sequential designs, blinded and unblinded sample size reestimation as well as adaptive designs for confirmatory trials with treatment or population selection at interim.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2017 program

 
 
Copyright © American Statistical Association